Full-Time

Head of Digital Portfolio and Change Management

Research

Posted on 3/14/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

Compensation Overview

$208.2k - $327.1k/yr

+ Short-term Incentives + Long-term Incentives

Expert

Boston, MA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Requirements
  • PhD degree in a scientific discipline with 15+ years experience, or MS with 21+ years experience, or BS with 23+ years experience
  • Degree in a relevant field such as life sciences or computational sciences
  • Proven experience managing large-scale digital portfolios in the pharmaceutical or biopharmaceutical R&D space
  • Expertise in digital strategy development, program management, and cross-functional governance
  • Strong understanding of R&D processes and the integration of digital technologies across the research lifecycle
  • Exceptional communication, leadership, and stakeholder management skills aligned with Takeda’s core values
  • Demonstrated ability to lead cross-functional teams, foster collaboration, and drive organizational alignment
Responsibilities
  • Provide program management support for major lighthouse initiatives
  • Manage the Research digital portfolio
  • Act as a cross-functional liaison for integration with the broader R&D strategy
  • Interface with CMC and Research Data Digital &Technology (RDDT) to ensure an end-to-end digital product development continuum
  • Champion governance, leadership and change management in digital transformation
  • Facilitate the development of a forward-looking Research digital strategy
  • Foster an inclusive and innovative culture
  • Engage with external industry networks and partners

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a strong pipeline with plans for multiple product launches in the coming years. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate continuously while ensuring that patient needs are prioritized and to contribute positively to public health and the environment.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's integration of AI enhances patient and healthcare provider engagement.
  • Positive Phase III trial results could lead to new revenue streams.
  • Recognition as a top workplace enhances its employer brand and talent attraction.

What critics are saying

  • A data breach could lead to reputational damage and legal issues.
  • The US antitrust case over Amitiza could result in financial penalties.
  • AI integration with Salesforce may face data privacy and compliance challenges.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company focuses on patient-centric values and environmental sustainability.
  • Takeda has a robust pipeline with 11 NMEs and aims for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

SuperAdrianMe
Jun 5th, 2025
Takeda Ukraine & Bulgaria Earn #8 Global Ranking in Best Places to Work 2024

LONDON, UK - Media OutReach Newswire - 5 June 2025 - Takeda, a global value-based, R&D-driven biopharmaceutical company, has been proudly recognized as one of the Top 10 Best Places to Work in the World for 2024, achieving the No. 8 global ranking by both Ukraine and Bulgaria countries.

Pharmashots
Jun 2nd, 2025
Takeda at ASH 2024: Phuong Khanh Morrow from Takeda in a Riveting Conversation with PharmaShots

Takeda at ASH 2024: Phuong Khanh Morrow from Takeda in a riveting conversation with pharmashots.

Value Analytics Labs
May 29th, 2025
Can Generative AI Rebuild Health Economic Models? Insights from an Ulcerative Colitis Case Study

At ISPOR 2025 in Montreal, its team at Value Analytics Labs - in collaboration with Takeda Pharmaceuticals - presented groundbreaking research on the use of generative AI in health economics.

Cloud Adoption Solutions
May 20th, 2025
CAS Communique Newsletter: May 2025

The platform will integrate Salesforce's cutting-edge AI capabilities with Takeda's deep expertise in pharmaceuticals to enhance engagement with both patients and healthcare providers.

ETF Daily News
May 11th, 2025
Tudor Investment Corp ET AL Decreases Stock Holdings in American Well Co. (NYSE:AMWL)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in American Well in the fourth quarter worth about $564,000.

INACTIVE